Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 8;8(46):80869-80877.
doi: 10.18632/oncotarget.20715. eCollection 2017 Oct 6.

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Mingxing Wang  1 , Wanjun Li  2 , Xuemei Xing  3 , Dan Zhang  4 , Jie Lei  1 , Guoyin Li  2   5
Affiliations

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Mingxing Wang et al. Oncotarget. .

Abstract

Objective: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC).

Methods: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1, STMN1, MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated.

Results: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients (p<0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients(p>0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer (p<0.01).

Conclusion: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.

Keywords: BRCA1 and STMN; NSCLC; chemotherapy; prognosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST All of the authors declared that they have no conflicts interest in relation to this study.

Figures

Figure 1
Figure 1. BRCA1, STMN1, MAPT and TUBB3 protein and mRNA expression levels in cancer tissues and adjacent nontumor tissues
(A-C) Detection of protein levels in NSCLC tissues and adjacent non-tumor tissues. (A and B) Immunohistochemical assays, (C) western blot analysis. (D) Scatter plot of the tissue chip analysis of clinical samples. (E) Scatter plot of the mRNA expression level analysis of clinical samples. N: adjacent non-tumor tissue, T: cancer tissue.
Figure 2
Figure 2. Analysis of the correlation between clinical features and expression levels of BRCA1, MAPT, STMN1 and TUBB3 in NSCLC
(A-D) The scatter plots of the influence of clinical features on the expression of target genes, onset age (A), tumor size (B), pathological type (C), pathological stage (D). Protein (left), mRNA (right), S: squamous cell carcinoma, A: Adenocarcinoma.
Figure 3
Figure 3. Kaplan–Meier curves with univariate analyses (log rank) of 70 NSCLC patients after surgical resection revealed 5-year survival
(A-D) Patients were grouped according to the expression of BRCA1, STMN1, MAPT and TUBB3 in the carcinomas, and subjected to follow-up investigations. The percent of surviving patients was plotted, BRCA1 (A), STMN1 (B), MAPT (C), TUBB3 (D). (E) The prognostic accuracy of BRCA1 combined with STMN1 is higher than that of either alone.
Figure 4
Figure 4. Analysis of the correlation between clinical features and 5-year survival rate of NSCLC patients
(A-E) Patients were grouped according to the clinical features of the NSCLC patients, pathological type (A), pathological stage (B), pathological location (C), tumor size (D), onset age (E).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Williams CD, Gajra A, Ganti AK, Kelley MJ. Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. Cancer. 2014;120:1939–47. - PubMed
    1. Sun R, Liu Z, Wang L, Lv W, Liu J, Ding C, Yuan Y, Lei G, Xu C. Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer. Tumour Biol. 2015;36:7195–204. - PubMed
    1. Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016;44:42–50. - PubMed

LinkOut - more resources